Table 1.
Inflammatory protein expression in the plasma of healthy control subjects and HS patients
| Protein | NN (n = 10) | HS (n = 20) | LLOQ | Unadjusted P value | |
|---|---|---|---|---|---|
| pg/mL | Median (IQR) or x/total | Median (IQR) or x/total | pg/mL | ||
| 1 | CXCL‐10 (IP‐10) | 402.7 (328.7‐550.5) | 277.4 (236.0‐328.8) | 2.40 | 0.003a |
| 2 | CCL‐26 (Eotaxin‐3) | 2/10 | 16/20 | 18 | 0.0041a |
| 3 | IL‐12/23p40 | 132.7 (97.7‐182.5) | 104.0 (74.6‐127.2) | 1.30 | 0.055 |
| 4 | IL‐1α | 1.8 (1.7‐3.6) | 4.2 (2.4‐10.2) | 0.62 | 0.055 |
| 5 | CCL‐4 (MIP‐1β) | 119.4 (66.6‐176.0) | 78.5 (59.9‐102.5) | 2.10 | 0.091 |
| 6 | TNF‐β | 2/10 | 0/20 | 0.28 | 0.103 |
| 7 | IL‐1β | 3/10 | 13/20 | 0.24 | 0.122 |
| 8 | CCL‐22 (MDC) | 926.2 (716.5‐1212.4) | 1312.7 (1000.8‐1538.6) | 38 | 0.155 |
| 9 | INF‐γ | 8.8 (5.3‐14.0) | 6.9 (4.8‐8.9) | 2.20 | 0.155 |
| 10 | IL‐15 | 2.0 (1.7‐2.3) | 1.7 (1.5‐2.1) | 0.32 | 0.198 |
| 11 | IL‐7 | 18.6 (14.8‐24.2) | 22.3 (17.0‐30.3) | 0.32 | 0.214 |
| 12 | IL‐10 | 0.3 (0.2‐0.4) | 0.2 (0.2‐0.3) | 0.16 | 0.231 |
| 13 | CCL‐3 (MIP‐1α) | 2/10 | 1/20 | 15.60 | 0.251 |
| 14 | CXCL‐8 (IL‐8) | 8.7 (7.2‐9.7) | 7.1 (6.0‐9.1) | 3.80 | 0.286 |
| 15 | IL‐16 | 208.0 (191.9‐287.3) | 257.9 (186.1‐317.9) | 4.20 | 0.475 |
| 16 | CCL‐11 (Eotaxin‐1) | 135.9 (95.6‐181.4) | 151.6 (118.5‐210.1) | 5.60 | 0.502 |
| 17 | IL‐6 | 1.3 (0.9‐2.6) | 1.1 (0.7‐2.6) | 0.36 | 0.530 |
| 18 | IL‐13 | 1/10 | 1/20 | 0.98 | 0.532 |
| 19 | IL‐17A | 4/10 | 6/20 | 2.10 | 0.690 |
| 20 | CCL‐17 (TARC) | 385.8 (222.6‐511.6) | 325.9 (259.9‐653.7) | 2.80 | 0.713 |
| 21 | TNF‐α | 2.6 (2.3‐3.2) | 2.5 (2.2‐3.0) | 0.64 | 0.779 |
| 22 | CCL‐13 (MCP‐4) | 188.0 (160.3‐234.8) | 210.6 (120.9‐238.3) | 4.80 | 0.880 |
| 23 | CCL‐2 (MCP‐1) | 85.0 (75.3‐99.1) | 83.0 (62.9‐114.9) | 0.22 | 0.983 |
| 24 | VEGF | 140.1 (116.0‐200.0) | 155.0 (103.6‐250.7) | 7 | 0.983 |
| 25 | IL‐2 | ND | ND | 0.68 | ‐ |
| 26 | IL‐4 | ND | ND | 0.38 | ‐ |
| 27 | IL‐5 | ND | ND | 0.40 | ‐ |
| 28 | IL‐12p70 | ND | ND | 0.74 | ‐ |
| 29 | GM‐CSF | ND | ND | 1.80 | ‐ |
| 30 | IL‐8 HA | ND | ND | 344 | ‐ |
IL‐8 HA (human antibody) has been validated for the MSD V‐PLEX™ kit and is recommended when high CXCL/IL‐8 levels are anticipated.
HS, hidradenitis suppurativa patients; IQR, interquartile range; LLOQ, lowest level of quantification; ND, not detected; NN, healthy controls; x, number of samples with a detectable value.
a
Significant after correction with the Benjamini‐Hochberg test (P < 0.0042).